Several past studies have suggested there are benefits to using botulinum neurotoxin type A (BoNTA) for improving the aesthetic appearance of established scars. This article describes a study on the prophylactic use of BoNTA for controlling scar formations as they occur. It is based on a small, double-blinded, controlled group of patients having just undergone a facelift procedure. The results suggest that the use of BoNTA just after surgery yield both quantitative and qualitative aesthetic benefits, and the data provide some guidance on optimal doses.
American Society of Plastic Surgery. Complete Plastic Surgery Statistics Report. Arlington Heights, IL: American Society of Plastic Surgery; 2016.
2.
GuptaVWinocourJShiHShackRBGrottingJCHigdonKK.Preoperative risk factors and complication rates in facelift: analysis of 11,300 patients. Aesthet Surg J. 2016;36(1):1-13.
3.
ChambersA.Unified approach to the treatment of hypertrophic and atrophic scars. Am J Cosmet Surg. 2016;33(4):176-183.
GassnerHGBrissettAEOtleyCCet al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81(8):1023-1028.
10.
WilsonAM.Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg. 2006;117(6):1758-1766.
11.
ZiadeMDomergueSBatifolDet al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg. 2013;66(2):209-214.
12.
HexselDDal’FornoTHexselCDo PradoDZLimaMM.A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2008;34(1):52-59.
13.
TrindadedeAlmeidaARMarquesEde AlmeidaJCunhaTBorasoR.Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33(1):S37-S43.
14.
FearmontiRBondJErdmannDLevinsonH.A review of scar scales and scar measuring devices. Eplasty. 2010;10:e43.
15.
GugerellAKoberJSchmidMBuchbergerEKamolzLPKeckM.Botulinum Toxin A: dose-dependent effect on reepithelialization and angiogenesis. Plast Reconstr Surg Glob Open. 2016;4(8):e837.
16.
BinLWangJHC. Fibroblasts and myofibroblasts in wound healing: force generation and measurement. J Tissue Viability. 2011;20(4):108-120.
17.
DarbyIALaverdetBBontéFDesmoulièreA.Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol. 2014;7:301-311.
18.
CencettiFBernacchioniCNincheriPDonatiCBruniP.Transforming growth factor-β1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol Biol Cell. 2010;21(6):1111-1124.
19.
GrandoSAZacharyCB.The non-neuronal and nonmuscular effects of Botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond. Br J Dermatol. 2018;178:1011-1019.
20.
WangLSunYYangWLindoPSinghBR.Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon. 2014;82:52-60.
21.
BrinMFJamesCMaltmanJ.Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;6(8):227-241.
